Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie Sells 689 Shares

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 689 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.26, for a total value of $12,581.14. Following the completion of the transaction, the chief operating officer now directly owns 336,136 shares of the company’s stock, valued at $6,137,843.36. The trade was a 0.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Fulgent Genetics Price Performance

Shares of Fulgent Genetics stock traded up $0.18 during mid-day trading on Wednesday, reaching $18.07. 155,004 shares of the stock traded hands, compared to its average volume of 185,564. The business has a 50-day moving average of $20.05 and a 200 day moving average of $21.18. Fulgent Genetics, Inc. has a fifty-two week low of $16.56 and a fifty-two week high of $30.68.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. StockNews.com cut Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday. Piper Sandler reduced their price target on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Monday, November 11th.

Hedge Funds Weigh In On Fulgent Genetics

Hedge funds have recently made changes to their positions in the company. Asset Dedication LLC acquired a new position in shares of Fulgent Genetics during the second quarter valued at approximately $33,000. Point72 DIFC Ltd purchased a new stake in shares of Fulgent Genetics in the third quarter valued at approximately $46,000. nVerses Capital LLC purchased a new stake in shares of Fulgent Genetics in the second quarter valued at approximately $43,000. Signaturefd LLC grew its position in shares of Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after purchasing an additional 1,132 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Fulgent Genetics in the second quarter valued at approximately $63,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.